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Abstract
Emerging autologous cellular therapies, utilizing platelet-rich plasma and mesenchymal 
stem cell applications, have the potential to play an adjunctive role in a standardized 
wound care treatment plan in patients suffering from chronic and recalcitrant wounds. 
The use of platelet-rich plasma growth is based on the fact that platelet growth factors 
can support the three phases of wound healing and then ultimately contribute to full 
wound closure. Mesenchymal stem cell-based therapies are also an attractive approach 
for the treatment of these difficult-to-heal wounds. This field of regenerative medicine 
focuses primarily on stem cells, which are specialized cells with the ability to self-renew 
and differentiate into multiple cell types. Mesenchymal stem cells can be isolated from 
bone marrow and adipose tissue via minimally manipulative and cell-processing tech-
niques, at point of care. Both platelet-rich plasma and mesenchymal stem cell applica-
tions have the potential to become an effective and ideal autologous biological cell-based 
therapy, which can be applied to chronic wounds to effectively change the wound bed 
microenvironment to enable and accelerate wound closure.
Keywords: chronic wounds, microenvironment, wound healing, clinical platelet-rich 
plasma, platelet-rich plasma gel, mesenchymal stem cells, bone marrow concentrate, 
adipose tissue
1. Introduction
In the Western world, approximately 1–2% of the population will develop a chronic wound 
during their lifetime. These numbers will increase worldwide as a result of the aging popula-
tion, increase in diabetes and obesity, and cardiovascular disease as well [1–3]. In particular, 
chronic leg wounds represent the largest fraction, with venous and diabetic foot ulcers (DFUs) 
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accounting for 70–90% of these ulcers [4]. Concomitantly, the costs of wound care services are 
rising, with the market of wound care products surpassing $15 billion annually.
There is an unmet need to stimulate the healing of acute and chronic wounds to a level that is 
not possible with the current standard care measures and therapy approaches.
An area of medicine that holds promise for the treatment of recalcitrant and difficult-to-heal 
wounds is regenerative medicine. Therefore, it is critical to use more effective and efficient 
treatment options from patient and cost perspectives. The use of autologous biologics, such 
as platelet-rich plasma (PRP)- and mesenchymal stem cell (MSC)-based therapies, holds sub-
stantial promise to enhance tissue regeneration and repair in many different diseases and 
could therefore also be potentially effective in chronic wound care management strategies.
This review aimed to describe the scientific rationale and clinical experiences of two different 
autologous biological therapies to support the healing of chronic and recalcitrant wounds. First is 
the use of clinical PRP, prepared at point of care using a dual spin buffy coat device, and second 
is the local application of MSCs, derived from either bone marrow concentrate or adipose tissue.
2. Skin layers
The skin consists of three layers. The epidermis is the most outer layer, consisting of mul-
tilayered epithelium extending from the basement membrane, which separates the dermis 
from the air. The basement membrane contains progenitor stem cells, which undergo con-
tinuous self-renewal and differentiate into keratinocytes. The keratinocytes migrate towards 
the surface of the skin where they normally undergo terminal differentiation and maturation 
[5]. The dermis is the thickest layer, just below the epidermis. The dermis is a connective tis-
sue, composed of the extracellular matrix (ECM), fibroblasts, vascular endothelial cells, and 
skin appendages such as sweat glands and hair follicles [6]. Fibroblasts are cells that secrete 
molecules including collagen and elastin, which provide mechanical strength and elasticity 
to the skin. The third layer is the hypodermis, which is underneath the dermis and composed 
of adipose tissue, providing insulation and cushioning between the skin and bone, muscle, 
tendon, and other skeletal structures [6]. A skin defect is repaired through cutaneous wound 
healing processes to recover loss of integrity, facilitate tensile strength, and provide a barrier 
for the skin [7]. Normal cutaneous wound repair is a multifaceted process.
3. Normal wound healing and cellular mechanisms
Wound healing is a well-orchestrated and complex series of events involving cell-cell and 
cell-matrix interactions, with platelet growth factors (PGFs), their dedicated receptors, and 
stem cells serving as messengers to regulate the various processes involved. The “wound 
healing” process as a whole has to be considered from the point of view of the type of lesion, 
which will in turn dictate the degree of healing that can be obtained. A partial thickness skin 
abrasion heals almost entirely by epithelialization, whereas deep pressure chronic ulcers rely 
mainly on matrix synthesis, angiogenesis, fibroplasia, and wound contraction.
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3.1. Platelet clot and degranulation
With wounds and also after surgical incisions, repair begins with platelet clot formation, 
activation of the coagulation cascade, and subsequent platelet degranulation, releasing 
PGFs. After tissue damage, specific growth factors, including platelet-derived growth fac-
tor (PDGF) and fibroblast growth factor (FGF), are already being produced by the injured 
tissue cells [8]. Once a platelet plug is in place, platelets will get trapped in the fibrin mesh 
and start to degranulate, releasing PGFs, among other molecular components. Different 
growth factors have different characteristics and thus biological activities. Chemotactic 
and mitogenic capabilities have been demonstrated with regard to inflammatory cells (i.e., 
neutrophils, monocytes, and macrophages) [9]. At wound sites, PDGF subunits AB and 
transforming growth factor-β (TGF-β) are the most important growth factors initiating the 
wound healing process.
3.2. Inflammatory cell mechanisms
During the first 2 days of wound healing, an inflammatory process is initiated by the migra-
tion of inflammatory cells (neutrophils, macrophages, and T-lymphocytes) to the wound 
site to accomplish phagocytosis with the removal of bacteria, cellular debris, and dam-
aged tissue. After the early inflammatory phase subsides, the predominant macrophage 
population assumes a wound healing phenotype that is characterized by the production 
of numerous growth factors and cytokines, including PDGF, transforming growth factor 
β1 (TGF-β1), insulin-like growth factor 1 (IGF-1), and vascular endothelial growth factor-a 
(VEGF-a), which promote cell proliferation and blood vessel development [10, 11]. Activated 
macrophages can be classified into different phenotypes. M1-type, with antimicrobial and 
antitumor properties, is activated upon wound formation by inflammatory signals from 
interferon-y (IFN-y) and tumor necrosis factor-α (TNF-α) or when pathogen-associated 
molecular patterns or endogenous danger signals are recognized. Their main role is host-
defense mechanisms in the early healing process, releasing IL-12, promoting pro-inflamma-
tory Th1 immune responses [12]. Conversely, the M2 macrophage phenotype downregulates 
inflammation and initiates tissue repair by releasing anti-inflammatory cytokines, such 
as IL-10 [13, 14]. Apoptotic wound neutrophils are ingested by these M2 macrophages, 
which release cytokines to promote macrophage recruitment and synthesize mediators 
critical to remodeling and angiogenesis, including TGF-β, VEGF, and epidermal growth 
factor (EGF) [15, 16].
3.3. Proliferative cell activity
Angiogenesis and fibroplasia are the next phases of wound healing, the proliferative phase. 
New blood vessel formation and the migration of fibroblasts, which deposit new ECM, are 
facilitated by EGF, keratinocyte growth factors (KGFs), and TGF-α [17, 18]. Keratinocytes 
migrate from the wound edges between the dermis facilitated by the production of colla-
genase and other proteases in the epidermis. Fibroblasts migrate, proliferate, and produce 
ECM in the wound bed, resulting in early granulation and tissue formation [19]. This process 
leads to an early increase in wound breaking strength, which is an important wound healing 
parameter of surgical wounds.
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3.4. Epithelialization
The final phase of wound closure is epithelialization, characterized by the exit of inflamma-
tory cells, a decrease in growth factor release, an increase in the ratio of collagen deposition to 
fibroblasts, and the cross-linking and organization of collagen molecules. Remodeling takes 
place over a much longer period of time in which the newly formed tissue is reorganized 
for higher tensile strength [17]. Hence, the normal wound healing process constitutes a deli-
cate balance of cells secreting and regulating the many cytokines, chemokines, proteins, and 
growth factors.
4. Chronic wound healing characteristics
A vast majority of chronic wounds begin as minor traumatic injuries, such as penetrating 
injuries, insect bites, or even simple scratches of dry skin. Normally, these wounds heal within 
a few days/weeks. However, aging and underlying pathologies, such as diabetes-induced and 
nondiabetic neuropathies, can lead to the development of poor or non-healing wounds [20]. 
Furthermore, arterial and venous vascular pathologies with hyperglycemia could further 
complicate the wound healing process. Chronic wounds are chronically inflamed and can 
be characterized by dysfunctional cellular events and aberrant cytokine and growth factor 
activities, leading to failure of normal wound closure with the potential for infections [19, 21]. 
Wound infections trigger extensive recruitment of inflammatory cells, particularly resulting 
in high concentrations of neutrophils, serine elastase, and inflammatory macrophages, while 
cell extravasation is facilitated by disproportionate expression of vascular cell adhesion mol-
ecules and interstitial cell adhesion molecules by resident endothelial cells. The accumulated 
inflammatory cells in the wound bed lead to protease activity, with elevated levels of matrix 
metalloproteases (MMP) 2, 8, and 9, successively prolonging inflammation [22]. Moreover, 
tissue inhibitor of MMP 1 is decreased in non-healing wounds, thereby increasing collageno-
lytic activity. Furthermore, neutrophils also produce various reactive oxygen species (ROS), 
inducing considerable oxidative stress and thus damaging structural elements of the ECM 
and wound biochemical microenvironment [23]. Nonetheless, together with proinflamma-
tory cytokines, an abnormally prolonged inflammatory phase will result in wound chronic-
ity, which might lead to premature cell senescence [24]. Tissue hypoxia and repeated wound 
infections will continue to promote MMP enzyme activity, resulting in decreased growth 
factor functions, and fibrin deficits will transpire. It has been demonstrated that a chroni-
cally inflamed wound microenvironment subjects proteins and cytokines to degradation and 
sequestration, in particular the growth factors PDGF, EGF, and TGF-β [25, 26]. In addition, 
Cooper et al. demonstrated that a number of growth factors were markedly reduced in wound 
fluids from chronic wounds as compared to acute wounds [27]. Moreover, FGF and TGF-β 
concentrations were significantly downregulated in chronic wounds. Decreased growth 
factor levels and upregulation of proinflammatory cytokines and chemokines will worsen 
normal progression of wound healing and consequently the potential for full wound closure. 
In chronic wounds, the microenvironment must be modified to be an active and effective 
intervention, eliminating the factors that impede healing.
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To succeed in the reparative phase of wound healing, chronic wound care treatment strate-
gies should have a dual approach. This includes the treatment of any underlying systemic 
disease and wound-microenvironmental tissue therapy. Evidence-based principles for local 
and systemic wound care management exist in the literature but are not further discussed 
in this chapter [28, 29]. In these traditional wound care treatment options, the application of 
autologous cellular biologics, such as platelet-rich plasma (PRP) growth factor therapy and 
MSC applications, is not anticipated, but discussed in detail here below.
5. Platelets in platelet-rich plasma therapy
PRP therapies have been used for a variety of indications, for more than 30 years. More than 
10,000 references are currently in PubMed, using the search term platelet-rich plasma. These 
countless applications have given rise to considerable interest in the potential of autologous 
PRP in numerous regenerative medicine indications. In the last decade, numerous studies 
and reviews have been published on PRP therapies as a biological, adjunctive, therapy option 
in the management of chronic wounds.
5.1. Platelets and their intracellular content
Platelets are formed from megakaryocytes and are synthesized in bone marrow by pinching 
off from their progenitor cell. Thereafter, platelets are released into the peripheral circula-
tion. Platelets are small, anucleate, discoid blood cells (1–3 μm), with an in vivo half-life of 
7 days. The average platelet count in adults ranges from 150 to 350 × 106/mL of circulating 
blood. Platelets have a ring of contractile microtubules (cytoskeleton) around their periphery, 
containing actin and myosin. Inside platelets, there are a number of intracellular structures, 
including α-granules comprising PGFs and angiogenesis regulators and dense granules con-
taining ADP, ATP, serotonin, histamine, calcium, and mitochondria. Other complex platelet 
biological components include adhesins and coagulation and immunological molecules. 
These molecules serve a multitude of functions, first within the clotting cascade and finally as 
initiators of tissue-healing processes. Platelets are equipped with an extensively invaginated 
membrane with an intricate canalicular system, which is in constant contact with the extracel-
lular fluid [30]. Normally, platelets are in a resting state, non-thrombogenic. They require a 
‘trigger’ before they become a potent and an active player in hemostasis and an accelerator of 
the wound healing cascade, depending upon the microenvironmental effectors.
5.2. Platelet-rich plasma gel, growth factors, and platelet receptors
When PRP is indicated to treat recalcitrant wounds, in the vast majority of these applications, 
PRP is delivered as a topical semiviscous coagulum so that concentrated platelets and various 
cytokines can adhere to the surface of the wound bed. For platelets to stick to a prepared 
wound bed, the PRP sample needs to be activated, thereby changing from a resting, inac-
tive state to an active form. The platelet discoid shape changes, with the development of 
pseudopodia (Figure 1). This change in platelet shape and configuration is facilitated by the 
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Figure 2. Schematic illustration of the activities of platelet growth factors during the different stages of the wound 
healing cascade. The numbers indicate the sequence of the phased stages of the wound healing process in which platelet 
growth factors have pivotal roles (EGF, epidermal growth factor; FGF, fibroblast growth factor; PDGF, platelet derived 
growth factor; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor).
addition of platelet agonists (e.g., autologous or bovine thrombin, calcium, tissue factor, or 
other platelet-activating proteins) to a volume of PRP. Platelet activation and aggregation 
then leads to the creation of the semiviscous coagulum, that is, platelet clot, referred to in the 
literature as platelet-rich plasma gel (PRP-G). In this constitution, PRP-G can then be exog-
enously applied to soft tissues and chronic wounds.
Figure 1. Graphic illustration of non-activated and an activated platelet. (A) A normal, discoid, resting platelet in a 
non-activated state, with platelet glycoprotein surface receptors on the outside of the platelet. (B) Following activation, 
the platelet shape is changed, with the development of pseudopods and the release of platelet granules and other 
intracellular storage vesicles via the opened canalicular system into the local microenvironmental milieu.
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Following a PRP-G application on a debrided wound bed, fibrinolysis occurs over time 
and the platelets start to disintegrate, subsequently releasing their PGFs and other plasma 
proteins. This is the onset of PGF-mediated stimulation of cell proliferation, promotion of 
cell differentiation and chemotaxis, and induction of migration of various (stem) cells to the 
wound area [31, 32]. The rational for applying PRP-G to wound bed tissues is the delivery 
of a diversity of concentrated platelet-derived growth factors and other biological media-
tors (e.g., adhesive proteins, fibrinogen, fibronectin, vitronectin, and thrombospondin-1) to 
mimic, and accelerate, physiologic wound healing cascades and regenerative tissue repair 
processes (Figure 2) [33].
After disintegration of the topical semiviscous coagulum, PGFs and other platelet molecules 
accumulate in the ECM and the released growth factors interact and bind with a specific 
platelet tyrosine kinase receptor (TKR), present on the outer surface of cell membranes 
(ligand-receptor interaction). TKRs are membrane spanning proteins that extend into the 
cytoplasm of the cell. After growth factors interact with their specific cell membrane TKR, 
activation of (inactive) messenger proteins in the cytoplasm occurs. The activated TKR cyto-
plasmic tail now serves as a binding site for the messenger proteins. An activated protein is 
generated through a signaling cascade, capable of entering the cell nucleus, where it triggers 
the genes responsible for controlling cell division. Subsequently, transcription of mRNA is 
induced, producing a biological response that initiates cascades that induce tissue repair and 
regeneration (Figure 3) [34, 35].
Figure 3. Illustrative representation of the mechanisms involved in platelet growth factor binding to their receptor. 
Specific platelet growth factors find their dedicated cell membrane tyrosine kinase receptor on the outside cell membrane. 
Following coupling, active enzymatic intracellular signaling occurs, with transmission to the cell nucleus via messenger 
ribonucleic acid.
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A synopsis of the most well-known PRP growth factors is provided in Table 1, along with 
a description of the growth factor sources and their individual specific functions [36–47]. 
Besides the numerous activities of their growth factors, platelets also contribute to many 
adjunctive and supportive activities (Table 2) via paracrine, autocrine, and endocrine modes 
of actions [35, 37]. Because of these unique modes of action, PGFs are capable of exerting 
effects on multiple cell types, showing a series of morphometric and mitogenic functions. 
The morphometric growth factors, involved in bone growth, can turn undifferentiated mul-
tipotent MSCs into immature and mature osteoprogenitor cells through the presence of the 
so-called bone morphogenetic proteins (BMPs) [48]. Most PGFs have mitogenic actions that 
increase the population of healing cells and degranulate by mitogenesis.
Platelet growth 
factor
Growth factor sources Biological activities
Platelet-derived 
growth factor, 
PDGF(a-b)
Platelets, osteoblasts, endothelial cells, 
macrophages, monocytes, smooth 
muscle cells
Mitogenic for mesenchymal cells and osteoblasts; 
stimulates chemotaxis and mitogenesis in fibroblast/
glial/smooth muscle cells; regulates collagenase 
secretion and collagen synthesis; stimulates 
macrophage and neutrophil chemotaxis
Transforming 
growth factor, 
TGF(ɑ-β)
Platelets, extracellular matrix of 
bone, cartilage matrix, macrophages/
monocytes, and neutrophils
Stimulates undifferentiated mesenchymal cell 
proliferation; regulates endothelial, fibroblastic, 
and osteoblastic mitogenesis; regulates collagen 
synthesis and collagenase secretion; regulates 
mitogenic effects of other growth factors; stimulates 
endothelial chemotaxis and angiogenesis; inhibits 
macrophage and lymphocyte proliferation
Vascular endothelial 
growth factor, VEGF
Platelets, endothelial cells Increases angiogenesis and vessel permeability; 
stimulates mitogenesis for endothelial cells
Epidermal growth 
factor, EGF
Platelets, macrophages, monocytes Stimulates endothelial chemotaxis/angiogenesis; 
regulates collagenase secretion; stimulates 
epithelial/mesenchymal mitogenesis
Fibroblast growth 
factor, FGF(a-b)
Platelets, macrophages, mesenchymal 
cells, chondrocytes, osteoblasts
Promotes growth and differentiation of 
chondrocytes and osteoblasts; mitogenic for 
mesenchymal cells, chondrocytes, and osteoblasts
Connective tissue 
growth factor, CTGF
Platelets through endocytosis from 
extracellular environment in bone 
marrow
Promotes angiogenesis, cartilage regeneration, 
fibrosis, and platelet adhesion
Insulin-like growth 
factor-1, IGF-1
Plasma, epithelial cells, endothelial cells, 
fibroblasts, osteoblasts, bone matrix
Chemotactic for fibroblasts and stimulates protein 
synthesis. Enhances bone formation by proliferation 
and differentiation of osteoblasts
Interleukin-8, IL-8 Platelets, macrophage, epithelial cells Stimulates mitosis of epidermal cells and supports 
angiogenesis
Adapted from Everts [130].
Table 1. Comprehensive description of the most known platelet ɑ-granule components as they appear in PRP.
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6. PRP device technology and cellular formulations of clinical PRP
PRP treatment protocols have evolved immensely over the past 20 years. Through laboratory, 
experimental, and clinical research, followed by more recent meta-analyses, physicians, medi-
cal practitioners, and scientists have gained a better understanding of platelets in PRP cellular 
physiology. The platelet secretome consists of all the proteins that are released upon platelet 
activation, which can be measured through proteomic-based techniques [49]. This proteomic 
profiling has increased our current understanding of the functional importance of the platelet 
granule contents [50], especially with regard to the biological cellular functions of the multifac-
eted platelet secretome and other plasma constituents, affecting PRP treatment outcomes.
6.1. Autologous blood predonation and PRP processing devices
The starting point for any PRP preparation is whole blood. At point of care, a fresh unit of 
autologous blood is drawn via a phlebotomy, following standard operating procedures.
The median cubital vein is often used as this is an easily accessible and superficial vein, 
enabling the introduction of 18- to 21-gauge butterfly systems. Blood is collected in a syringe 
Proteins-chemokines-cytokines Biological activities
Adhesive proteins Cell contact interactions
Extracellular matrix composition
Proteases and anti-proteases Angiogenesis
Vascular remodeling
Cellular regulation
Cellular behavior
Mitogenic factors Increases angiogenesis
Cell proliferation
Chemotaxis
Chemokines and cytokines Cellular interaction
Vascular remodeling
Bone formation
Membrane glycoproteins Platelet aggregation
Platelet adhesion
Inflammation
Platelet and leukocyte interaction
Granules Capillary permeability
Vascular local regulation
Table 2. Non-platelet growth factor-related adjunctive effects of PRP therapy.
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containing an anticoagulant to prevent clotting. The blood predonation volume depends 
on the PRP device of choice to prepare PRP and the volume needed for specific single, or 
multiple, wound care treatments in the same patient. Directly after blood collection, the PRP 
centrifugation process should be initiated in order to produce a sample of PRP.
Currently, physicians can choose from more than 30 PRP processing systems. However, a lack 
of consensus on standardizing PRP has contributed to the variation in PRP devices, which 
produce dissimilar platelet concentrations and cellular compositions [51, 52].
Optimal blood separation is best safeguarded by so-called double-spin PRP centrifuges with 
dedicated disposable platelet concentration devices. These double-spin PRP devices create 
a layered buffy coat stratum based on different centrifugal forces and specific gravities and 
densities of the individual blood components (Figure 4). Single-spin devices, or plasma-PRP 
Figure 4. Cellular density separation of whole blood by centrifugation. After the first centrifugation procedure, the 
whole blood components are separated in the PRP device from the plasma as a result of the different densities in two 
basic layers. The top layer is the platelet plasma suspension, consisting of plasma and the multicomponent buffy coat 
layer, containing platelets, monocytes, lymphocytes, and neutrophils. The second layer consists of erythrocyte pack. The 
range of the specific cell densities varies between individuals.
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devices, prepare a product from the acellular plasma layer, excluding erythrocytes and leuko-
cytes, while collecting as many platelets as possible from the plasma layer [53]. These differ-
ences in cellular compositions, and thus PRP characteristics, have recently been recognized in 
the literature [54]. Marques et al. found that inferior treatment outcomes following PRP appli-
cations correlated directly with poor quality and inconsistent PRP products [55]. Therefore, 
PRP devices should be versatile and compliant to enable the production of different PRP 
formulations, while maintaining supraphysiologic platelet numbers (Figure 5). More specifi-
cally, the final cellular PRP treatment sample should be tailored to serve treatment protocols 
contingent to wound bed condition, wound size and depth, and undermining tissue.
6.2. Definition of clinical-PRP and platelet dose
PRP can be characterized as a complex composition of autologous multicellular components 
in a small volume of plasma, with a substantial supraphysiologic concentration of platelets 
compared to baseline values, with minimal red blood cell contamination.
Clinical PRP (C-PRP) contains a clinical dose of concentrated platelets in a treatment sample. Marx 
demonstrated enhancement of bone and soft tissue healing with a minimum platelet count of 1 × 
109/mL [56]. Furthermore, Giusti et al. revealed in an experimental study that 1.5 × 109 platelets/
mL are needed for inducing a functional angiogenic response, via endothelial cell activity, in tis-
sue repair mechanisms [57]. Therefore, to significantly induce an angiogenic response in circula-
tory compromised chronic wounds, C-PRP should contain at least 7.5 billion deliverable platelets 
in a 5-mL treatment sample. These platelets should then be able to release their entire content 
after (tissue) activation has occurred, as visualized in Figure 6 by electron microscopic imaging. 
Furthermore, this platelet dose will correspondingly induce cell proliferation and cell migration. 
Ultimately, an increase in wound bed microcirculation would contribute to ECM remodeling and 
wound epithelialization [58]. Consequently, C-PRP containing a platelet dose of 1.5 × 109 platelets/
mL has the ability to stimulate (neo)angiogenesis and elicit the healing of chronic wounds.
6.3. Leukocytes in C-PRP
Leukocytes have a great impact on the intrinsic biology of chronic wounds because of 
their immune and host-defense mechanisms. Therefore, the presence of leukocytes in 
Figure 5. Whole blood and PRP smears with non-activated platelet. (A) Peripheral blood smear of whole blood inside the 
circle, platelets are visible (platelet count of the smear is 276,000/μL), next to white blood cells, erythrocytes, and fibrin. 
(B) Platelet-rich plasma smear. A high density of platelets inside the circle, with minimal leukocytes and erythrocytes 
(platelet count of 2,208,000/μL, prepared with the EmCyte System).
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re-establishing wound healing attempts in chronic non-healing wounds can be turntables in 
the wound healing process [59].
The eventual presence of leukocytes in PRP specimen depends on the operating and design 
principles of PRP devices. Most ideally, PRP processing devices should be able to produce 
different PRP cellular formulations, including leukocyte composition and concentration. 
PRP formulations should be based on a disease-specific pathology, medical condition, and 
tissue types.
Leukocytes develop from multipotential hemopoietic stem cells in the bone marrow and mature 
along several differentiation pathways. Via common myeloid progenitor cells and myeloblasts, 
they become differentiated granular (neutrophils, eosinophils, basophils) and a-granular cells 
(lymphocytes and monocytes) [60]. However, during PRP preparation, the cell membranes of 
eosinophils and basophils are destroyed following the centrifugation procedure. Interactive 
wound healing processes involve mediators, extracellular matrix components, resident cells, 
including platelets, and infiltrating leukocytes. They participate in the classical pathway of 
wound healing: hematoma, inflammation, tissue formation, and ultimately tissue remodeling.
In PRP, lymphocytes are more concentrated than other leukocytes. They produce insulin-like 
growth factors, and they may contribute to tissue remodeling [61].
Monocytes are non-inflammatory white blood cells and are the precursors to macrophages. 
Macrophages are important cells of the immune system that, similar to neutrophils, are formed 
to fight infection or engulf accumulating damaged or dead cells. Unlike neutrophils, monocytes 
do not lead to a prolonged inflammatory condition but play important roles in tissue healing. 
Figure 6. (A) Electron microscopic image of a single platelet in the circles. The internal platelet ɑ and dense granules (black 
and gray structures, respectively) and lysosomes are visible with intact cellular membranes. (B) Electron microscopic 
image of activated platelets in the circles. The platelet membranes are ruptured, and their granular content is no longer 
visible. The platelet growth factors and other vesicles have been released to the extracellular matrix.
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M1 macrophages are responsible for producing several inflammatory cytokines that support 
host defense through pathogen clearance, necrotic tissue clearance, and reactive oxygen spe-
cies. Furthermore, the M1 phenotype produces growth factors such as VEGF and FGF. M2 mac-
rophages have anti-inflammatory capacities and generate precursors for collagen and fibroblast 
stimulating factor, thus supporting their role in extracellular matrix deposition. Generally, 
the plasticity of monocytes is dependent on the microenvironment in which they are present. 
Monocytes and macrophages release additional pro-regenerative growth factors that lead to 
neovascularization, proliferation of myogenic precursor cells, and stimulation of the activity of 
satellite cells, playing key roles in wound repair and inflammatory control [21, 62].
Neutrophils have a clear function in healing cascades since they form a dense barrier against 
invading pathogens and counteract infections [63]. Their presence in PRP can be desirable in 
wound care treatment to functionally destroy and clear bacteria from the wound bed, in cer-
tain types of open surgical procedures to prevent wound infections, or within specific treat-
ment protocols that require higher levels and longer periods of inflammation [64]. However, 
when PRP samples containing very high neutrophil concentrations are used, for example, in 
non-infected and granulating wound beds, this neutrophil-rich PRP poses a potential risk of 
progressive and persistent microenvironmental inflammation via the secretion of proteases 
and toxic oxygen metabolites. PRP products containing elevated levels of proinflammatory 
neutrophils facilitate a strong leukocytic chemotaxis to induce a phagocytic response, not 
contributing to wound epithelialization [65, 66].
6.4. Erythrocytes in C-PRP and effects of eryptosis on the wound microenvironment
Detrimental consequences of erythrocytes or red blood cells (RBCs) on tissues have been stud-
ied by several groups. In a study by Hooiveld and coworkers, chondrocytes and synoviocytes 
were exposed to RBCs causing tissue degeneration and destruction, including apoptosis [67]. 
In another study, it was postulated that erythrocytes inhibit fibroblast proliferation in a col-
lagen scaffold. These findings indicate potential negative effects on the healing of soft tissue 
cellular structures when using PRP that contains high concentrations of erythrocytes [68]. 
Indeed, the use of PRP containing RBCs should be avoided in wound healing strategies to 
prevent wound breakdown.
Another rare phenomenon occurs when a PRP preparation including RBCs is applied to tis-
sues. Under normal physiological circumstances, erythrocytes are removed from the circula-
tory system by the process of senescence after approximately 120 days. In tissues treated 
with PRP-containing erythrocytes, natural mechanisms of erythrocyte elimination are no 
longer valid, and erythrocytes undergo eryptosis before they reach their full lifespan [69]. 
Typical features of eryptosis are similar compared to apoptosis: membrane blebbing and cell 
shrinkage, resulting in the release of platelet activating factor (PAF). PAF plays a role in con-
trol mechanisms of inflammation and stimulating ceramide release and intracellular stress 
response, while eryptotic RBCs bind to endothelial cells and impede microcirculation [70]. 
Therefore, the application of PRP containing RBCs in the chronic wound microenvironment 
finally leads to tissue inflammation and an intracellular stress response, causing oxidative 
destruction in the wound vasculature.
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Figure 7. (A) Typical aspect of a neutrophil-poor PurePRP®SP sample, with a more yellow coloring. This PRP is 
intended to treat a wound that does not require proinflammatory PRP stimulation. (B) Typical aspect of a neutrophil-
rich PurePRP®SP sample. This formulation is defined as a full buffy coat PRP, containing a significant concentration of 
platelets, neutrophils, monocytes, and lymphocytes. The red color in this preparation is due to the erythrocytes present 
in the PRP, as the collected neutrophils are on top of the red cells when they are from the platelet-plasma suspension 
(PurePRP®SP, pure platelet-rich plasma supraphysiologic; PRP, platelet-rich plasma).
7. PRP preparation protocol to produce PurePRP®SP
In this paragraph, a detailed and specific PRP preparation procedure is described to pro-
duce Pure Platelet-Rich Plasma-Supra Physiologic (PurePRP®SP, EmCyte Corporation, Fort 
Myers, FL, USA). This autologous cellular platform technology is able to generate C-PRP with 
high concentrations of platelets; there are protocol options to produce neutrophil-poor or 
-rich PRP, with minimal erythrocyte contamination (Figure 7). Furthermore, this platform 
technology enables clinicians to also concentrate bone marrow aspirate to retrieve, among 
other cells, concentrated mesenchymal cells [71]. Additionally, the same technology is capable 
of creating concentrated and viable adipose tissue complex. Both bone marrow and adipose 
biological tissue types will be discussed in another paragraph to emphasize the ability to use 
viable MSCs for wound care treatment.
7.1. PRP preparation and procedural therapy application steps
At point of care, 54 mL of fresh whole blood is predonated in a 60-mL syringe preloaded with 
6 mL of 3.8% sodium citrate (anticoagulant). The PurePRP®SP device is loaded from the top 
and placed in a centrifuge with pre-programmed settings. Following a first centrifugation of 
1.5 min, the whole blood is sequestered in a Platelet-Poor Plasma Suspension (PPS) contain-
ing a buffy coat layer and RBCs. Using a syringe, the PPS is aspirated until a band of RBCs, 
which holds mature platelets, is captured with the PPS. This volume is then transferred to 
the bottom part of the same device, the concentration chamber, and placed in the centrifuge 
for a 5-min second spin. During this period, a final cell PPS separation is achieved, with the 
concentrated platelets pelleted at the bottom of the chamber. Excessive platelet-poor plasma 
(PPP) is removed, leaving a PurePRP®SP volume, generally between 3 and 7 mL. This PPP 
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volume is used to resuspend the platelets from the bottom of the device back into the PPP by 
gentle swirling of the device. When the bottom part is clear, all platelets are resuspended in 
the plasma and the PurePRP®SP is then withdrawn with a 12-mL syringe (Figure 8).
Depending on the biological wound treatment strategies, different PRP application techniques 
can be used. Before starting any PRP procedure, a meticulous sharp wound debridement 
should be done. Microfracturing the wound bed, with removal of cellular/plasma debris or 
dead tissue, allows PGFs to function more effectively while being resistant to rapid degrada-
tion by proteolytic wound activities.
The application of PRP, or PRP-G, can be done using different techniques. First, PRP can be 
injected intralesionally, including the wound edges [72]. This technique delivers the platelets 
directly into the deeper tissue structures. The objective of this technique is to stimulate tissue 
regeneration faster in more stagnant wounds and wound edges or to prepare the wound bed 
for a final reconstructive procedure [73]. Second, PRP mixed with bovine or autologous throm-
bin creates a PRP-G coagulum, where this topical “primary” biological wound dressing covers 
and sticks to the wound bed. The PRP-G can be applied to a wound bed via a single syringe 
technique or delivered using a double syringe spray device to ultimately generate a solid graft 
(Figure 9). Lastly, wounds with undermining can be filled with PRP-G using a single syringe 
and blunt needle approach. Furthermore, the same technique using a sharp needle is suitable 
for injecting the wound perimeter with adipose tissue, with or without PRP (Figure 10).
After PRP has been applied to the wound bed, wound undermining areas, and wound edges, 
platelets will slowly start to lyse, releasing their PGFs, cytokines, and other proteins; inducing 
cell signaling processes; and initiating regeneration and tissue healing [74].
The literature is not clear on the number of PRP treatments needed to treat a wound and the asso-
ciated outcomes. Several studies indicate multiple treatments over a period of time. Everts et al. 
performed initially two treatments weekly for 2 weeks. Thereafter, the procedure was bi-weekly, 
until final wound closure was expected. In the same study, the PRP procedure was followed 
by using a naturally derived porcine intestinal submucosa matrix graft to support building the 
Figure 8. PurePRP®SP preparation procedure. (A) The PRP device is loaded with anticoagulated whole blood. (B) After 
first spin, the PPS is created following gravity centrifugal separation. (C) The PPS evacuated from the top chamber and 
meticulously injected in bottom part of the PRP device for the second spin procedure. (D) After the second spin, the PPS 
is further refined in a PPP fraction and concentrated platelets. (E) PPP has been softly removed with a syringe, leaving 
a desired volume behind to gently resuspend the supraphysiologic platelet concentrate, which is attached to the bottom 
of the second chamber of the device. (F) The platelets are aspirated in a small volume of plasma and the PurePRP®SP 
product is collected in a syringe prior to application (PPS, platelet plasma suspension; PRP, platelet-rich plasma; PPP, 
platelet poor plasma; PurePRP®SP is a registered trademark of EmCyte corporation, Fort Myers FL, USA).
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Figure 10. (A) Filling an undermining of a wound with PRP-G, using a single syringe technique in which both PRP 
and thrombin have been mixed to a semiviscous coagulum (the black line indicates the direction of the undermining). 
(B) The wound perimeter of the chronic wound is injected with a mixture of PRP and concentrated adipose tissue to 
deliver PGFs and adipose tissue constituents like MSCs (PRP-G, platelet-rich plasma gel; PRP, platelet-rich plasma; 
PGFs, platelet growth factors; MSCs, mesenchymal cells).
ECM and limited permeability to keep the lysing platelet fluids in place (OASIS® Wound Matrix, 
Cook Biotech, Inc., West Lafayette, IN, USA), followed by a hydrocolloid secondary dressing 
(DuoDERM® Extra Thin Dressing, ConvaTec, Greensboro, NC, USA) [73]. Others have used, 
for example, a non-absorbent sterile transparent sheet (Tegaderm™, 3M Medical Inc.) or a knit-
ted cellulose acetate non-adherent dressing impregnated with a petrolatum emulsion (Adaptic, 
Systagenix Wound Management Limited, North Yorkshire, UK) [75].
Recent review articles do not provide clear information on post-PRP treatment protocols 
[76, 77]. This author’s experiences with PRP wound care treatments included no dress-
ing changes for 5 days post-treatment. Thereafter, minimal wound cleaning and no sharp 
debridement are standard wound care activities, until the next PRP application. During all 
Figure 9. PRP application techniques. (A) A semiviscous PRP-G coagulum is topically placed on a wound bed via a 
single syringe technique. PRP and thrombin are mixed in the same syringe and delivered via a blunt needle covering 
the entire wound bed. (B) Intralesional injection of PRP with a 30-gauge needle in the wound bed and/or wound edges. 
(C) Spray application using an aerosol delivery technique, with PRP and autologous thrombin in separate syringes. The 
content mixes at the tip of the spray catheter, where after PRP-G is formed at the tissue site (PRP-G, platelet-rich plasma 
gel; PRP, platelet-rich plasma).
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patient visits, the wounds were assessed according to the TIME wound grading system [78], 
which was designed for tissue evaluation, infectious condition, and moisture evaluation, 
and the condition of the wound edges was checked at every visit to monitor progress and 
regression of wound healing.
8. Overview of some of the most relevant studies using autologous 
PRP to treat chronic wounds
The characteristics of biological PRP and PRP-G suggest that they might be a beneficial tool 
in the surgical armamentarium. PRP-G has been successfully used in maxillofacial surgery, 
orthopedics, cosmetic surgery, and dental implantology. Furthermore, several randomized 
controlled clinical trials studied the effect of PRP-G in wound rehabilitation and tissue engi-
neering. Eleven studies were identified involving the use of different PRP formulations in 
venous and diabetic leg ulcers between 2007 and 2018 [79–89]. A summary of all the studies 
is shown in Table 3. A general comment from these studies is that some of them were under-
powered [79, 81]. The PRP interventions were highly variable with regard to platelet dosing, 
formulations, the total number of PRP applications, and the interval between applications. 
PRP-G was produced using bovine thrombin and/or CaCl
2
 or calcium gluconate to initiate 
a platelet coagulum. The presence of leukocytes in PRPs and the platelet dose relative to 
peripheral blood were hardly described. The frequency of application varied between twice 
weekly and weekly. Time to wound healing or wound size reduction was the most common 
outcome measurement. Six trials involved predominantly diabetic patients [81–83, 87, 88], 
while mixed ulcer etiology was included in the other studies. Outcome results favored experi-
mental treatments with PRP, in all studies presented. Furthermore, Carter et al. conducted 
a review in 2011, analyzing published prospective and retrospective studies and meta-ana-
lyzed the use of PRP and PRP-G in wound healing in acute and chronic conditions [90]. Their 
paper included 24 studies, from which 3 studies were systematic reviews and 9 studies were 
included in the meta-analysis. The systematic review and meta-analysis stated that PRP appli-
cations in cutaneous wounds exposed complete and partial wound healing when compared 
to control wound care. Furthermore, the presence of infection was reduced in acute wounds 
treated with PRP. Martinez-Zapata and co-workers presented their results from a systematic 
review, including10 randomized controlled trials (RCTs) in chronic wounds in their meta-
analysis [91]. Three of these RCTs involved DFU and three studies involved venous leg ulcers. 
Their results indicated that autologous PRP can enhance DFU healing when compared with 
standard care.
A condensed summary review by Everts et al. revealed the efficacy and safety of PRP-G treat-
ments when used by different institutions [92]. Picard et al. published a literature review, 
comprising 12 studies, to summarize evidence-based data regarding the treatment of diabetic 
chronic wounds with PRP. In 87.5% of controlled studies, they found a significant benefit 
for the use of PRP therapy to treat chronic diabetic wounds, which remained unhealed after 
standard wound care treatment [93]. However, more studies remain necessary to produce 
strong evidence eliminating poor design and high bias [90, 91].
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Presently, more studies are ongoing to clarify optimized PRP protocols to improve its 
angiogenic and regenerative properties to be implemented as a standard practice of care in 
advanced wound care treatment plans.
9. Comprehensive background on stem cells
In any regenerative tissue microenvironment, there are essentially stem cells, growth fac-
tors, and a biological scaffold to provide the necessary biological milieu for cell-tissue 
regeneration and cell renewal. MSCs originating from either bone marrow or adipose tissue 
are now extensively being used in a variety of patients who have an indication for mini-
mally invasive, regenerative medicine therapies to enhance tissue repair and regeneration. 
Traditionally, bone marrow aspirate (BMA) has been utilized as a source of bone marrow-
derived mesenchymal stem cells (BM-MSC), hematopoietic stem cells (HSCs), progenitor 
cells, and platelets. Lately, MSCs derived from adipose tissue have emerged in a variety of 
regenerative treatment protocols. However, in chronic wound care strategies, autologous, 
non-cultured, MSC therapies are rarely used. However, Hocking reported from preclini-
cal and clinical trials that MSC therapy has the potential to effectively treat wounds with 
Year; author 
[reference]
Study 
design
N patients in study; 
indication
Duration of 
wound
Outcomes
2007; Kakagi [77] RCT 51; foot tissue 
defects
>3 months Ulcer reduction in treatment group
2010; Jeong [77] RCT 100; DFU >4 weeks Complete wound healing
2011; Saad Setta 
[79]
RCT 24; non-healing DFU >8 weeks PRP treated group healed significantly 
faster
2015; Karimi [80] RCT 50; DFU No limit PRP significantly reduced wound surface 
and depth in 3 weeks
2015; Li [81] RCT 117; DFU >2 weeks PRP significant better healing than 
standard care
2016; Pravin [82] RCT 31; 22 VLU and 
DFU; 9 others
>8 weeks Leukocyte free PRP healed better, 86% 
ulcer healing
2017; Moneib [83] RCT 40; venous ulcers >6 months Significant ulcer reduction
2017; Obolensky 
[84]
CT 100; non-healing, 
mixed etiology
>6 weeks Earlier epithelialization; shorter 
hospitalization; less total costs
2017; Babaei [85] PT 150; DFU >3 weeks Full closure after 8.8 weeks
2017; Milek [86] CT 100; DFU >6 months Full wound closure treatment group 
controls only small wounds
2018; Etugov [87] PT 23; VLU >4 weeks Significant ulcer size reduction compared 
to control
RCT, randomized controlled trial; CT, controlled trial; PT, prospective trial; DFU, diabetic foot ulcer; VLU, venous 
leg ulcer; PRP, platelet-rich plasma.
Table 3. Overview of some of the most relevant studies using autologous PRP technology to treat chronic wounds.
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delayed healing, resulting in accelerated wound closure [94]. A stem cell is, by definition, 
the one cell capable of duplicating itself (self-renewal) and resuming its undifferentiated 
status, while also originating progeny that can differentiate into one or more final products 
that are physiologically defined by their specific functions. Stem cells can be classified on the 
basis of their origin and their potential to proliferate and differentiate. According to Wagers 
and Weissman, the classification of stem cells is based on their plasticity and potential for 
differentiation [95]: totipotent, able to give rise to all embryonic and extraembryonic cell 
types; pluripotent, able to give rise to all cell types of the embryo proper; multipotent, able to 
give rise to a subset of cell lineages; oligopotent, able to give rise to a restricted subset of cell 
lineages; and unipotent, able to contribute only one mature cell type. Adult stem cells have 
a multipotent lineage and are able to transdifferentiate into various progenies, forming cells 
of multipotent lineages, such as HSCs and MSCs [95]. HSCs are pluripotent cells that further 
differentiate via hematopoiesis into distinct progenitor cells which mature into blood cells 
of myeloid lineages (monocyte, granulocyte, erythrocyte, and megakaryocyte/platelets) and 
lymphoid cells (B, T and NK cells) [96].
10. Mesenchymal stem cells
MSCs are multipotent adult stem cells and can be obtained from various adult tissues, includ-
ing bone marrow stroma, adipose tissue, and other tissue types. According to the International 
Society of Cellular Therapy, MSCs are defined as those cells that are able to adhere to plastic and 
express a number of cell surface markers (including CD73, CD90, and CD105) while undergoing 
multilineage differentiation. Furthermore, MSCs should have the ability for self-renewal [97]. 
MSCs can also be identified as specialized populations of mural cells/pericytes. They provide 
a niche for HSCs and have the ability to differentiate into various mesodermal lineages. Under 
appropriate conditions and an optimal microenvironment, MSCs can differentiate into meso-
dermal lineage cells such as osteoblasts, endothelial cells, adipose tissue, and smooth muscle 
cells [4]. These capabilities have led to the use of MSC as a potential strategy for treating various 
diseases since they promote biological processes, such as angiogenesis and cell proliferation and 
differentiation [98]. Furthermore, they synthesize mediators (cytokines and trophic factors) that 
participate in tissue repair processes, immune modulation, and the regulation of inflammatory 
processes. [99]. The trophic effects are facilitated by the MSC secretion of reparative cytokines 
and growth factors, including TGF-β, VEGF, and EGF, to contribute to local tissue repair [100]. 
Caplan also suggested that the modulation of inflammation is instigated by the suppression 
of inflammatory T-cell proliferation and inhibition of monocyte and myeloid cell maturation 
[101]. Based on above characteristics, one can see that MSCs are able to establish a regenera-
tive microenvironment at the site of release, which could improve the recruitment, activation, 
and differentiation of endogenous stem cells with the potential for repair in wound healing. 
Currently, clinical research is investigating MSCs as a therapy to treat difficult-to-heal wounds.
10.1. Bone marrow mesenchymal stem cells
BM-MSCs from adult bone marrow tissue were first isolated by Pittenger et al. [102]. Since then, 
BM-MSCs are frequently used successfully as a biological product, like PRP, in regenerative 
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medicine therapies to treat a variety of musculoskeletal disorders, such as chondral defects, 
osteoarthritis, and rotator cuff lesions [103, 104]. BM-MSCs are relatively easy to acquire via a 
BMA procedure. Bone marrow can be harvested from a variety of anatomic sites during a sur-
gical procedure in the operating room, or an office setting, with minimal morbidity. A variety 
of donor locations are available, including the anterior or posterior iliac crest, calcaneus, tibia, 
distal femur, and proximal humerus. The iliac crest is used frequently and known to be a rich 
source of BM-MSCs (Figure 11). BM-MSCs are transplanted autologously, therefore avoiding 
any ethical issues. Furthermore, the relatively simple preparation and separation and high 
genetic stability of BM-MSCs allow for their easy use in vitro and as an injectate. Imperative 
for an effective BM-MSC injection is the quality of the initial bone marrow aspiration proce-
dure with regard to minimizing trauma to cellular content of the bone marrow niche, such as 
platelets, progenitor cells, and leukocytes, while maximizing cellular yields and minimizing 
peripheral blood infiltration [105].
Furthermore, the collected bone marrow cells should be viable, with no presence of disin-
tegrated erythrocytes (hemolysis), as this would have a profound negative effect on tissue 
regeneration [106]. The author believes that a BMA sample should always be preceded by 
a 2-step centrifugation procedure to concentrate the sample to a bone marrow concentrate 
(BMC). This will concentrate the indispensable cellular content, such as MSCs (measured by 
CFU-f), HSCs, total nucleated cells, and platelets, above the baseline counts of these cells. 
Nonetheless, the centrifugation procedure will decrease hemolytic parameters as well as 
RBC levels. The effects of concentrating BMA with regard to some of the most important 
constituents and factors are shown in Table 4. Erythrocytes should also be avoided in a BMC 
specimen, for the same reasons as discussed in the above paragraph on C-PRP and effects 
Figure 11. Aspire bone marrow aspiration from the posterior superior iliac spine area. (A) The introducer and 
aspiration needle are placed through the skin, sub cutaneous layer, and cortical bone into the marrow cavity. (B) The 
BMA device is placed in the PSIS. Bone marrow is meticulously aspirated via suction vacuum applied to a syringe, 
through the aspirator needle. (C) Bone marrow cells, including purified mesenchymal stem cell, hematopoietic stem 
cells, total nucleated cells, platelets, and progenitor cells, are collected through the fenestrated aspirator needle with a 
blunt tip from the cancellous bone. (D) The final BMC sample is produced following a 2-step proprietary centrifugation 
protocol. Inside the blue circle, concentrated bone marrow cells are visible, on the top of the erythrocyte layer (BMA, 
bone marrow aspirate; PSIS, posterior superior iliac spine; BMC, bone marrow concentrate; Aspire™ bone marrow 
aspiration system is trademark of EmCyte Corporation, Fort Myers FL, USA).
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of eryptosis on the wound, as this will cause profound inflammation and compromise the 
microcirculation [69].
10.2. Adipose mesenchymal stem cells
Similar to BM-MSCs, adipose-derived mesenchymal stem cell (AD-MSC) has been used in 
regenerative medicine applications. AD-MSCs can be isolated following an adipose tissue 
(mini) liposuction procedure of subcutaneous fat tissue, mostly from the abdomen.
Various preparation techniques, including centrifugation, exist to collect, wash, and rinse 
adipose tissue to generate a concentrated adipose tissue concentrate (ATC). Adipocytes 
constitute almost 90% of adipose tissue volume and nearly 65% of the total cell number 
[107]. When enzymatically digested, adipose tissue yields a heterogeneous population of 
many cell types (pre-adipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells, 
resident monocytes/macrophages, and lymphocytes), which upon isolation are termed the 
stromal vascular fraction (SVF) [108]. AD-MSCs have a multilineage cell differentiation 
potential, that is, they are capable of differentiating into adipogenic, chondrogenic, myo-
genic, osteogenic, and neurogenic cells [109]. Thus, AD-MSCs might be indicated in clinical 
applications for the repair of damaged tissues, as well as for angiogenic therapy to improve 
neovascularization [110].
The popularity of AD-MSCs in regenerative medicine treatment protocols and recently in a 
biological wound care treatment protocol as well is due to an abundance of MSCs, with a high 
proliferation capacity and differentiation potential, when compared to MSCs derived from 
bone marrow [111, 112]. Furthermore, Yun et al. described AD-MSC-mediated effects on the 
reduction of proinflammatory cytokines, chemokines, cellular apoptosis, and collagenases 
[113]. Moreover, AD-MSCs have been shown to be immune-privileged [114].
Laboratory parameters BMA BMC Concentrating effect
TNC (−nRBCs) × 106/mL 28 142.8 5.1 × BL
Platelets × 106/mL 96 614 6.4 × BL
CD34+ cells × 105/mL 1.68 9.2 5.5 × BL
CFU-f (MSCs) × 103/mL 1.05 5.59 5.3 × BL
Hematocrit % 40.7 6.8 −83% × BL
Hemolysis % 6.3 1.8 −73% × BL
Cell viability % 95.9 97.3 + 0.6% × BL
BMA, bone marrow aspirate; BMC, bone marrow concentrate; × BL, effects times baseline values; TNC, total nucleated 
cells; −nRBCs, minus red blood cells; CD34+, stem cell marker/expression on hematopoietic progenitor cells found in 
bone marrow; CFU-f, fibroblast colony-forming units: assay for bone marrow mesenchymal stem cell analysis; MSCs, 
mesenchymal stem cells.
Table 4. Effects of bone marrow aspirate concentration on cell counts, hematocrit, and the elimination of hemolytic red 
cells.
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11. MSCs in cutaneous wound healing
Currently, cell-base therapy is an attractive approach for the treatment of recalcitrant chronic 
wounds. MSCs from adipose and bone marrow tissues are being investigated as a therapeu-
tic strategy for a distinct group of pathological conditions, including chronic hard-to-heal 
wounds [115]. The orchestrated process of wound healing entails cellular and hormonal 
physiological processes of inflammation, epithelialization, proliferation, collagen matrix 
formation, and particular neoangiogenesis, regulated by various growth factors such as 
TGF-β, VEGF, PDGF, granulocyte macrophage colony-stimulating factor, the interleukin 
family, EGF, FGF, and TNF-α [116, 117]. However, the activity of these cytokines in chronic 
wounds is often reduced due to a prolonged inflammatory state, decreasing the neoangio-
genic potential.
BM-MSCs and AD-MSCs have been studied as potential solutions for these major issues. Both 
types of MSCs have been shown to be effective in augmenting wound healing by modulating 
the immune response and secreting paracrine factors which promote therapeutic (neo) angio-
genesis and thereby providing biological ingredients for wound tissue regeneration, and they 
are ultimately capable of inducing full wound closure (Figure 11; [118–121]).
Optimal wound bed preparation encompasses not only debridement and proper manage-
ment of the bacterial load but also correction of the wound matrix and reconditioning of 
phenotypically altered resident cells which are present in chronic wounds. Based on their 
characteristics and biological activity, MSCs are capable of interacting with resident wound 
cells to transform resident cells to functional matrix building cells [122]. This might be of par-
ticular importance for the dermal rebuilding process to stimulate keratinocytes to accomplish 
epithelialization.
Given their higher isolation yield, ease of harvesting, and abundance of adipose tissue, some 
groups believe that AD-MSCs might be more clinically attractive. Not only because of their 
angiogenic capability, but they may also function in situ as pericytes providing vascular 
stability and they might communicate with endothelial cells in response to environmental 
stimuli [123, 124]. However, experienced clinicians may dispute the cited potential risk for 
complications with BMA, as they feel comfortable in performing BMA procedures in medi-
cal-office settings using local anesthetics and imaging to perform the aspiration. Shapiro and 
coworkers performed a prospective, single-blind, placebo-controlled trial on 25 patients with 
bilateral knee osteoarthritis and reported that the BMA, production, and use of BMC is a safe 
procedure [125].
11.1. Critical limb ischemia
BM-MSCs are frequently being studied in patients with critical limb ischemia, who also might 
suffer from chronic wounds and who are not eligible for the revascularization procedure due 
to several comorbidities, namely high operative risk, multiple failures of revascularization, 
and high rate of restenosis. These patients are suitable for biological cell-based therapy with 
MSCs. In particular, BM-MSCs protocols are newly emerging therapies to treat CLI in this 
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subset of patients, promoting the regeneration of impaired endothelium and neoangiogen-
esis in ischemic tissues [126, 127]. The effects of several types of bone marrow cell therapy 
(e.g., bone marrow-derived mononuclear cells, CD34+ bone marrow cells, and mesenchymal 
stromal cells) have been studied in CLI patients. The outcomes of several cell-based therapy 
trials demonstrated that the rate of major amputation was significantly decreased [128]. It can 
be concluded that MSC application can be considered a promising target for future biological 
therapies in CLI patients [129].
12. Conclusions
Regenerative medicine technologies offer solutions to a number of compelling clinical prob-
lems that have not been able to adequately result in a solution through the use of drugs, 
surgery, or permanent replacement devices.
The purpose of this chapter was to review multiple aspects of both PRP and MSC biocellular 
therapies as part of a wound care treatment plan to support in the healing of chronic and 
recalcitrant wounds.
Numerous significant aspects that are still not well understood or standardized have been 
discussed, as well as the rationale for cell-based therapies. For platelet-rich plasma prepara-
tions, specific formulations, platelet dosing, processing, and the differences between systems 
were discussed. With regard to bone marrow and adipose tissue, as cell sources for obtaining 
high quality mesenchymal cells, some technicalities were provided.
Among both tissue-based cellular therapies, bone marrow mesenchymal cells have been the 
most frequently employed and reported on. In this review, evidence is shown on results from 
several clinical studies in which autologous biologics have been applied in patients with 
chronic wounds. The outcomes of these studies suggested that the application of biocellular 
products can reverse the microenvironment in chronic wounds, achieving the ultimate goal: 
full wound epithelialization in the shortest possible time. Furthermore, it was revealed that 
these treatments are safely executed without adverse effects for patients.
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